HCA, MBA President and Chief Executive Officer Mr. Korz was named President and CEO in April 2008 after serving as our Vice President of Drug Development since March 2003. His multi-disciplinary experience spans seventeen years in the biotech sector as well as ten years in the healthcare sector. He brings with him a broad drug development background, including experience in regulatory, clinical, business development and medical affairs. His experience with therapeutic and diagnostic research drugs encompasses various indications including cancer, MS, rheumatoid arthritis, and psoriasis. He has managed medical studies from the preclinical to the pivotal clinical stages.

Prior to joining us he held the position of Clinical Development Manager with Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI) from 2000 to 2003. Mr. Korz's experience includes overseeing the development of diagnostic and therapeutic products with AltaRex Corp. in Edmonton and Boston. His initial drug development, clinical and regulatory experiences were gained with Biomira Inc.

CA Chief Financial Officer Bashir Jaffer is a member of the Institute of Chartered Accountants of British Columbia and the Canadian Institute of Chartered Accountants since 1976. He is also a Fellow of the Institute of Chartered Accountants of England & Wales.

Mr. Jaffer brings to Chemokine 30 years of extensive and diverse experience in public practice, entrepreneurial, professional, management and leadership roles in business and with community organizations. Mr. Jaffer was previously Chief Financial Officer of Veridicom International Inc., a publicly traded company in the field of biometric software and hardware development. Prior to that he was the owner and President of a travel management company from 1998 to 2003, and from 1983 to 1998, Mr. Jaffer was a partner at a firm of chartered accountants located in Vancouver, British Columbia.

Mr. Jaffer has previously worked for a public company and an international CA firm in London, UK and also with KPMG (previously Thorne Riddell) and PricewaterhouseCoopers (previously Coopers & Lybrand) in Vancouver. Mr. Jaffer has also served as the Chairman of the Board of Directors of United Way of Canada and also as the Board Chair of the United Way of the Lower Mainland. Currently he serves on the Board of Providence Health Care.

Ph.D Chairman and Chief Scientific Officer Dr. Salari, an entrepreneur and scientist, founded the Company in July 1998. He is experienced in managing private and public biotechnology companies. Dr. Salari also has served as President of Globe Laboratories Inc., a biotechnology research and development company, since June 2002. Prior to his engagement with us, Dr. Salari founded and built the biotechnology company, Inflazyme Pharmaceuticals Ltd. (IZP.TO). From 1992 to 1998 he had, in his role as President and Chief Executive Officer, the responsibility of managing Inflazyme Pharmaceuticals Ltd.'s business affairs as well as its drug discovery and development program. He negotiated and closed several licensing deals with biotechnology and pharmaceutical companies.

From 1990 to 1998, Dr. Salari was Professor of Medicine at University of British Columbia. He assembled several research teams in the fields of autoimmunity and inflammation. He was also a consultant and advisor to pharmaceutical companies in the United States and Europe. From 1987 to 1990, he was Assistant Professor at University of British Columbia and also served as a consultant to Merck & Co. Inc., Upjohn Co., and Zymogenetics Inc., in the field of novel anti-inflammatory and autoimmune drugs. From 1986 to 1987, he was a research associate in the Department of Medicine at University of British Columbia. He was the lead project investigator in cytokine research and drug development. From 1984 to 1986, he worked as a research associate at the Department of Physiology, Laval University. Dr. Salari carried out research work on the biology of human blood cells and their control by cytokines. In 1982 and 1983, he consulted to a French pharmaceutical corporation (Beafour Ipsen) as a research scientist on the discovery of novel anti-inflammatory drugs. From 1981 to 1982, Dr. Salari worked at the Department of Immunology, McGill University in Montreal as a research associate.

Dr. Salari has a Ph.D. degree from the University of Southampton, United Kingdom, Department of Microbiology (1976-1980). His Ph.D. dissertation investigated the protein chemistry of infectious bacteria. Throughout his academic career, Dr. Salari has published over 150 scientific articles and book chapters on various immunology topics and autoimmune diseases. He has previously obtained six U.S. patents for his pioneering work on the discovery of novel drugs to treat autoimmune diseases: US 06046185; US 05506217; US 05399683; US 05369097; US 05219845 and US 06706701. He is also co-inventor of nine patents issued or patents applied for which are part of our intellectual property.

Ph.D Vice president, Drug Development Dr. Wong is an experienced researcher with 7 years of post doctoral and 5 years of doctoral experience in the fields of cytokines, growth factors, cardiovascular and neuropathological disorders. He is the author of a number of important scientific publications on the role of the blood-brain barrier in multiple sclerosis, stroke and other inflammatory diseases in the brain, as well as the role of a leaky endothelium in atherosclerosis, especially in the context of diabetes and organ transplants. He obtained his Ph.D. in Neuropathology at the University of British Columbia and carried out post-doctoral work at the laboratories of Dr. Steven Vincent and Dr. Bruce McManus. Dr. Wong has written over 20 scientific publications, and over 10 patents. He is responsible for conducting, and managing all the pre-clinical, drug development of Chemokine Therapeutics drugs.

 Vice President, Corporate Communications Mr. Evans has over 20 years experience in business and finance and prior to recently joining Chemokine he served as Vice President, Corporate Communications for Wex Pharmaceuticals Inc. At Wex Pharmaceuticals Mr. Evans developed an effective shareholder communications program where he broadened the shareholder base and substantially increased the number of retail shareholders. His department helped create extensive media coverage. Mr. Evans was involved in raising capital for the company and his responsibilities included listing the company on the TSX Exchange. While working for Pacific International Securities for three years Mr. Evans managed and maintained accounts for over 400 clients providing investment advice. Mr. Evans has also owned and operated a number of small businesses in Western Canada. Mr. Evans passed the Canadian Securities course with honors in 1991 and completed his Chartered Financial Planner in 1996.